[HTML][HTML] Protective efficacy of inactivated vaccine against SARS-CoV-2 infection in mice and non-human primates

YF Yao, ZJ Wang, RD Jiang, X Hu, HJ Zhang, YW Zhou… - Virologica Sinica, 2021 - Springer
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused more than 96 million
infections and over 2 million deaths worldwide so far. However, there is no approved …

Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in …

C Li, YX Chen, FF Liu, AC Lee, Y Zhao, ZH Ye, JP Cai… - Clin Infect Dis, 2021 - hero.epa.gov
BACKGROUND: Mass vaccination against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is ongoing amidst widespread transmission during the Coronavirus Disease …

[HTML][HTML] Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine: preclinical studies

A Kandeil, A Mostafa, RR Hegazy, R El-Shesheny… - Vaccines, 2021 - mdpi.com
Since the emergence of SARS-CoV-2 at the end of 2019, 64 candidate vaccines are in
clinical development and 173 are in the pre-clinical phase. Five types of vaccines are …

[HTML][HTML] Immunological evaluation of an inactivated SARS-CoV-2 vaccine in rhesus macaques

H Chen, Z Xie, R Long, S Fan, H Li, Z He, K Xu… - … Therapy-Methods & …, 2021 - cell.com
Because of the relatively limited understanding of coronavirus disease 2019 (COVID-19)
pathogenesis, immunological analysis for vaccine development is needed. Mice and …

[HTML][HTML] Cold-adapted live attenuated SARS-Cov-2 vaccine completely protects human ACE2 transgenic mice from SARS-Cov-2 infection

SH Seo, Y Jang - Vaccines, 2020 - mdpi.com
A safe and effective vaccine that can provide herd immunity against severe acute respiratory
syndrome coronavirus (SARS-CoV-2) is urgently needed to stop the spread of this virus …

Absence of vaccine-enhanced disease with unexpected positive protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inactivated …

C Li, YX Chen, FF Liu, ACY Lee, Y Zhao… - Clinical Infectious …, 2021 - academic.oup.com
Background Mass vaccination against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is ongoing amidst widespread transmission during the coronavirus disease …

Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models

ZJ Wang, HJ Zhang, J Lu, KW Xu, C Peng… - Emerging microbes & …, 2020 - Taylor & Francis
The ongoing COVID-19 pandemic is causing huge impact on health, life, and global
economy, which is characterized by rapid spreading of SARS-CoV-2, high number of …

[HTML][HTML] Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques

PD Yadav, R Ella, S Kumar, DR Patil… - Nature …, 2021 - nature.com
The COVID-19 pandemic is a global health crisis that poses a great challenge to the public
health system of affected countries. Safe and effective vaccines are needed to overcome this …

Development, analysis, and preclinical evaluation of inactivated vaccine candidate for prevention of Covid-19 disease

E Alp Onen, K Sonmez, F Yildirim, EK Demirci, A Gurel - All Life, 2022 - Taylor & Francis
A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
emerged in the sprawling capital of Central China's Hubei province Wuhan in 2019. Since …

[HTML][HTML] Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques

P Yadav, R Ella, S Kumar, D Patil, S Mohandas… - 2020 - europepmc.org
The COVID-19 pandemic is a global health crisis that has severely affected mankind and
posed a great challenge to the public health system of affected countries. The availability of …